Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)
April 16, 2023 11:01 AM EDTUpdated April 17, 08:41 AM
R&D

As­traZeneca lines up com­pe­ti­tion with Mer­ck in lung can­cer be­fore and af­ter surgery: #AACR23

Nicole DeFeudis

Editor

OR­LAN­DO — As­traZeneca post­ed event-free sur­vival da­ta on Imfinzi’s use be­fore and af­ter surgery in pa­tients with non-small cell lung can­cer on Sun­day, with its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times